Most Shorted Stocks
ARDX is part of our most shorted stocks screen list, indicating it has a high short interest.
ARDELYX INC (ARDX) Stock Price & Overview
NASDAQ:ARDX • US0396971071
Current stock price
5.96 USD
-0.06 (-1%)
At close:
6.08 USD
+0.12 (+2.01%)
Pre-Market:
The current stock price of ARDX is 5.96 USD. Today ARDX is down by -1%. In the past month the price increased by 5.67%. In the past year, price increased by 13.31%.
ARDX Key Statistics
52-Week Range3.21 - 8.4
Current ARDX stock price positioned within its 52-week range.
1-Month Range5.35 - 6.54
Current ARDX stock price positioned within its 1-month range.
- Market Cap
- 1.462B
- P/E
- N/A
- Fwd P/E
- 2,213.31
- EPS (TTM)
- -0.25
- Dividend Yield
- N/A
ARDX Stock Performance
Today
-1%
1 Week
-5.10%
1 Month
+5.67%
3 Months
-23.29%
Longer-term
6 Months +18.25%
1 Year +13.31%
2 Years -6.88%
3 Years +33.63%
5 Years -18.47%
10 Years -25.59%
ARDX Stock Chart
ARDX Stock Screens
ARDX currently appears in the following ChartMill screener lists.
ARDX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ARDX. When comparing the yearly performance of all stocks, ARDX is a bad performer in the overall market: 75.52% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
ARDX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ARDX. Both the profitability and financial health of ARDX have multiple concerns.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ARDX Earnings
Next Earnings DateApr 30, 2026
Last Earnings DateFeb 19, 2026
PeriodQ4 / 2025
EPS Reported$0.00
Revenue Reported125.215M
EPS Surprise -100.00%
Revenue Surprise 3.91%
ARDX Forecast & Estimates
18 analysts have analysed ARDX and the average price target is 16.2 USD. This implies a price increase of 171.8% is expected in the next year compared to the current price of 5.96.
For the next year, analysts expect an EPS growth of 101.08% and a revenue growth 37.43% for ARDX
Analysts
Analysts90
Price Target16.2 (171.81%)
EPS Next Y101.08%
Revenue Next Year37.43%
ARDX Groups
Sector & Classification
ARDX Financial Highlights
Over the last trailing twelve months ARDX reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS decreased by -53.37% compared to the year before.
Income Statements
Revenue(TTM)407.32M
Net Income(TTM)-61.60M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.28% | ||
| ROE | -36.9% | ||
| Debt/Equity | 1.21 |
Chartmill High Growth Momentum
EPS Q2Q%-100%
Sales Q2Q%7.82%
EPS 1Y (TTM)-53.37%
Revenue 1Y (TTM)22.09%
ARDX Ownership
Ownership
Inst Owners69.25%
Shares245.25M
Float236.13M
Ins Owners2.92%
Short Float %10.36%
Short Ratio6.61
ARDX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.55 | 355.432B | ||
| AMGN | AMGEN INC | 15.27 | 188.147B | ||
| GILD | GILEAD SCIENCES INC | 15.12 | 165.877B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.34 | 110.672B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.34 | 80.984B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.97 | 41.869B | ||
| INSM | INSMED INC | N/A | 31.046B | ||
| NTRA | NATERA INC | N/A | 28.508B | ||
| BIIB | BIOGEN INC | 11.65 | 27.573B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.6 | 25.108B | ||
| MRNA | MODERNA INC | N/A | 20.96B | ||
| INCY | INCYTE CORP | 12.33 | 19B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ARDX
Company Profile
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The company is headquartered in Waltham, Massachusetts and currently employs 489 full-time employees. The company went IPO on 2014-06-19. The firm has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor). IBSRELA is a first-in-class NHE3 inhibitor approved by the United States FDA for the treatment of irritable bowel syndrome with constipation in adults. XPHOZAH is a first-in-class phosphate absorption inhibitor approved in the United States to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. The company has agreements for the development and commercialization of tenapanor outside of the United States. Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma.
Company Info
IPO: 2014-06-19
ARDELYX INC
400 Fifth Avenue, Suite 210
Waltham MASSACHUSETTS 94555 US
CEO: Michael Raab
Employees: 489
Phone: 15107451700
ARDELYX INC / ARDX FAQ
What does ARDELYX INC do?
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The company is headquartered in Waltham, Massachusetts and currently employs 489 full-time employees. The company went IPO on 2014-06-19. The firm has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor). IBSRELA is a first-in-class NHE3 inhibitor approved by the United States FDA for the treatment of irritable bowel syndrome with constipation in adults. XPHOZAH is a first-in-class phosphate absorption inhibitor approved in the United States to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. The company has agreements for the development and commercialization of tenapanor outside of the United States. Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma.
What is the stock price of ARDELYX INC today?
The current stock price of ARDX is 5.96 USD. The price decreased by -1% in the last trading session.
What is the dividend status of ARDELYX INC?
ARDX does not pay a dividend.
How is the ChartMill rating for ARDELYX INC?
ARDX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting ARDX stock to perform?
18 analysts have analysed ARDX and the average price target is 16.2 USD. This implies a price increase of 171.8% is expected in the next year compared to the current price of 5.96.
Would investing in ARDELYX INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ARDX.
Can you provide the upcoming earnings date for ARDELYX INC?
ARDELYX INC (ARDX) will report earnings on 2026-04-30.